ArticleJournal of thoracic disease2025
Lymph nodes metastatic burden as a prognosticator for advanced non-small cell lung cancer: a real-world study.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metastatic organ distribution characteristics and prognosis in patients with non-small cell lung cancer.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current nodal classification inadequately predicts outcomes for advanced non-small cell lung cancer (NSCLC) patients. We investigated whether metastatic lymph node characteristics could improve prognostic accuracy. Methods: We retrospectively analyzed 339 patients with advanced NSCLC who received immunotherapy as first-line treatment. Lymph node imaging was performed using computed tomography (CT), and the X-tile software was employed to determine optimal cutoff values for lymph node size and number. Prognostic factors were assessed using Kaplan-Meier survival curves and multivariate Cox regression analysis. The predictive accuracy of various N-staging was evaluated through time-dependent receiver operating characteristic (ROC) curves. Results: The optimal cutoff values for lymph node size and number were 1.60 cm and 3, respectively. Kaplan-Meier analysis indicated that size, number, and fusion of metastatic lymph nodes were associated with worse overall survival (OS) in advanced NSCLC patients {hazard ratio (HR) [95% confidence interval (CI)]: 2.179 (1.432-3.316), 1.859 (1.226-2.821), and 3.635 (1.796-7.358)}. Multivariate Cox regression analysis identified lymph node size [HR (95% CI): 6.21 (1.19-32.25)] and fusion [HR (95% CI): 3.20 (1.32-7.75)] as independent prognostic factors for OS. Incorporating lymph node size into the conventional N-staging system improved prognostic accuracy, with a 3-year area under the curve (AUC) of 0.651 (95% CI: 0.535-0.767). Conclusions: Lymph node size serves as a valuable indicator of tumor invasion and can enhance the existing N-staging system for more accurate prognosis prediction for more accurate prognosis prediction in advanced NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.